East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clobazam Oral Suspension, 2.5mg/mL. Aurobindo Pharma’s Clobazam Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ONFI® Oral Suspension, of Lundbeck Pharmaceuticals LLC .

Clobazam Oral Suspension  are indicated for:

• The adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.